Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Other 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 144pembrolizumab 122Carboplatin 110Bevacizumab 92Cisplatin 68Specimen Handling 62olaparib 52Magnetic Resonance Spectroscopy 51Gemcitabine 41Nivolumab 37Biopsy 36liposomal doxorubicin 34Taxes 34Cyclophosphamide 32Blood Specimen Collection 30niraparib 27Doxorubicin 27lenvatinib 26Topotecan 26Letrozole 25Drug Therapy 24Immunoglobulin G 23Brachytherapy 22fludarabine 21atezolizumab 21Radiotherapy 21Disulfides 21durvalumab 19dostarlimab 19Surveys and Questionnaires 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bupropion × Gynecologic × 1 year × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡